| 产品名称： | A5.12.14 5.12.14 |
|---|---|
| 商品货号： | TS167686 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Tissue： | spleen |
| Cell Type： | hybridoma:lymphoblast B lymphocyte; somatic cell hybri |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain: BALB/c (B cell); BALB/c (myeloma) |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Images： |  |
| Derivation： | Animals were immunized with recombinant human interleukin 8 (IL-8). Spleen cells were fused with P3X63Ag8U.1 (ATCC CRL-1597) mouse myeloma cells. The antibody blocks IL-8 binding to human neutrophil receptors. An expression plasmid pantilL-8.2 (ATCC 9056) was created to code for a chimeric murine-human fab fragment of the monoclonal antibody. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human interleukin 8 (IL-8) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human interleukin 8 (IL-8) |
| Comments： | Animals were immunized with recombinant human interleukin 8 (IL-8). Spleen cells were fused with P3X63Ag8U.1 (ATCC CRL-1597) mouse myeloma cells. The antibody blocks IL-8 binding to human neutrophil receptors. An expression plasmid pantilL-8.2 (ATCC 9056) was created to code for a chimeric murine-human fab fragment of the monoclonal antibody. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 x 10(5) viable cells/ml. Do not allow the cell concentration to exceed 5 X 10(5) cells/ml.
Interval: Maintain cultures at a cell concentration between 3 X 10(4) and 4 X 10(5) cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Freeze medium: Complete growth medium described above supplemented with 5% (v/v) DMSO. Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype： | mouse IgG2a kappa |
| Name of Depositor： | Genentech, Inc. |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Fong S, et al. Anti-IL-8 antibody fragments. US Patent 5,677,426 dated Oct 14 1997 Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002 Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002 Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000 Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | A5.12.14 5.12.14 |
|---|---|
| 商品货号： | TS167686 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Tissue： | spleen |
| Cell Type： | hybridoma:lymphoblast B lymphocyte; somatic cell hybri |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain： | Strain: BALB/c (B cell); BALB/c (myeloma) |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Images： | |
| Derivation： | Animals were immunized with recombinant human interleukin 8 (IL-8). Spleen cells were fused with P3X63Ag8U.1 (ATCC CRL-1597) mouse myeloma cells. The antibody blocks IL-8 binding to human neutrophil receptors. An expression plasmid pantilL-8.2 (ATCC 9056) was created to code for a chimeric murine-human fab fragment of the monoclonal antibody. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human interleukin 8 (IL-8) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human interleukin 8 (IL-8) |
| Comments： | Animals were immunized with recombinant human interleukin 8 (IL-8). Spleen cells were fused with P3X63Ag8U.1 (ATCC CRL-1597) mouse myeloma cells. The antibody blocks IL-8 binding to human neutrophil receptors. An expression plasmid pantilL-8.2 (ATCC 9056) was created to code for a chimeric murine-human fab fragment of the monoclonal antibody. |
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated Dulbeccos Modified Eagles Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 x 10(5) viable cells/ml. Do not allow the cell concentration to exceed 5 X 10(5) cells/ml.
Interval: Maintain cultures at a cell concentration between 3 X 10(4) and 4 X 10(5) cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation： | Freeze medium: Complete growth medium described above supplemented with 5% (v/v) DMSO. Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype： | mouse IgG2a kappa |
| Name of Depositor： | Genentech, Inc. |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| U.S. Patent Number： | |
| References： | Fong S, et al. Anti-IL-8 antibody fragments. US Patent 5,677,426 dated Oct 14 1997 Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002 Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002 Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000 Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000 |
